Predict your next investment

AJU IB Investment company logo
Venture Capital
FINANCE | Investment Firms & Funds
ajuib.co.kr

See what CB Insights has to offer

Investments

269

Portfolio Exits

15

Funds

28

About AJU IB Investment

AJU IB Investment (KOSDAQ: 027360) is a venture capital firm headquartered in Seoul, Korea with approximately USD $1 billion in capital under management. AJU Life Sciences Overseas Expansion Platform Fund, which is represented by AJU IB Investment's US office in Boston, MA, invests exclusively in companies developing pioneering new therapies or medical technologies with an emphasis on platforms.

AJU IB Investment Headquarters Location

AJU Bldg., 4th-5th Floor 201, Teheran-ro, Gangnam-gu

Seoul, 06141,

South Korea

+82 2 3451 9200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

AJU IB Investment Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AJU IB Investment Rank

Latest AJU IB Investment News

数字治疗初创公司S-Alpha Therapeutics,Inc.在A轮融资中筹集了870万美元

Aug 9, 2021

本文共1124个字,阅读需3分钟 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005608/en/S-Alpha Therapeutics raised a total of $8.7M USD (10 Billion KRW) in Series A financing round with the participation by existing investors and new Venture Capitalist (VC) funding.In 2020, S-Alpha Therapeutics raised $2.7M USD (3 Billion KRW) in seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.“The convergence of information technology (IT) and biotechnology is an inevitable industry trend. The investment in this industry is the driving force for fast product development, verification of new concepts and enhances the development of disruptive technologies. It also provides resources and infrastructure for validating the safety as well as efficacy of the product” said STIC Ventures, which led this investment.Dr. Yong-Sun Lee, Chief Strategy Officer from S-Alpha Therapeutics said “With this investment, we plan to develop and validate SAT-001, the leading product in pediatric myopia, through clinical trials in Korea and in US. S-Alpha Therapeutics will also use this fund to complete verification of SAT-008 and support R&D efforts to validate the concept in new disease areas of our pipeline.About S-Alpha Therapeutics, Inc.Founded in 2019, S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline.Currently, company is conducting clinical trials to evaluate the efficacy, safety and feasibility of SAT-001 in several clinical sites in South Korea.Among the company's pipelines, SAT-008, developed for the purpose of inducing an individual's immune-boosting effect, is in the process of establishing a business development model according to the evidence generated from clinical studies in South Korea. In addition, S-Alpha Therapeutics is in the process of developing other products in the pipeline.www.salphadtx.comView source version on businesswire.com: https://www.businesswire.com/news/home/20210809005608/en/For media contact: Sanghun Leeemail: sanghun@salphadtx.comPhone : 82-2-3487-3923Source: S-Alpha Therapeutics, Inc.View this news release online at:http://www.businesswire.com/news/home/20210809005608/en 本新闻稿以多媒体为特色。在这里查看完整版本:https://www.businesswire.com/news/home/20210809005608/en/在现有投资者和新的风险资本家(VC)的参与下,S-Alpha Therapeutics在a轮融资中总共筹集了870万美元(100亿韩元)。2020年,S-Alpha Therapeutics从Hana Ventures、STIC Ventures、AJU IB Investment、SJ Investment Partners和TONY Investment筹集了270万美元(30亿KRW)的种子轮资金。在A系列融资中,所有现有投资者都参与了这项投资,Korea investment Partners、Stonebridge Ventures、Devsisters Ventures/KDB Capital和Timewise investment作为新投资者参与。“信息技术(IT)与生物技术的融合是必然的产业趋势。对该行业的投资是快速产品开发、新概念验证和促进颠覆性技术发展的驱动力。它还为验证产品的安全性和有效性提供了资源和基础设施。S-Alpha Therapeutics的首席战略官李永善博士说:“通过这笔投资,我们计划在韩国和美国通过临床试验开发和验证儿童近视的领先产品SAT-001。S-Alpha治疗公司还将利用这笔资金来完成SAT-008的验证,并支持研发工作,以在我们管道中的新疾病领域验证这一概念。关于S-Alpha治疗公司。成立于2019年的S-Alpha Therapeutics开发数字治疗学,这是一种来自生物学和信息技术融合的治疗干预。公司已经开发了几个数字化治疗产品在其研发管道。目前,该公司正在韩国的几个临床点进行临床试验,以评估SAT-001的有效性、安全性和可行性。在该公司的管道中,为诱导个人免疫增强效应而开发的SAT-008正在根据韩国临床研究产生的证据建立业务发展模式。此外,S-Alpha疗法正在开发其他产品。www.salphadtx.com在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20210809005608/en/供媒体联系:Sanghun Lee电子邮件:sanghun@salphadtx.com电话:82-2-3487-3923资料来源:S-Alpha治疗公司。在网上查看此新闻稿:http://www.businesswire.com/news/home/20210809005608/en 以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

AJU IB Investment Investments

269 Investments

AJU IB Investment has made 269 investments. Their latest investment was in Boram Care as part of their Seed VC on August 8, 2022.

CBI Logo

AJU IB Investment Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/5/2022

Seed VC

Boram Care

$2.7M

Yes

1

6/23/2022

Series A

Boostimmune

$13.06M

No

2

6/17/2022

Series B

BBodek

$23.43M

Yes

4

6/7/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/2/2022

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

8/5/2022

6/23/2022

6/17/2022

6/7/2022

6/2/2022

Round

Seed VC

Series A

Series B

Series A

Seed VC

Company

Boram Care

Boostimmune

BBodek

Subscribe to see more

Subscribe to see more

Amount

$2.7M

$13.06M

$23.43M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

4

10

10

AJU IB Investment Portfolio Exits

15 Portfolio Exits

AJU IB Investment has 15 portfolio exits. Their latest portfolio exit was triple on June 08, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/8/2022

Merger

$99M

2

2/11/2022

Acquired

$99M

2

1/13/2022

Acquired

$99M

2

12/4/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/21/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/8/2022

2/11/2022

1/13/2022

12/4/2020

8/21/2020

Exit

Merger

Acquired

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

2

10

10

AJU IB Investment Acquisitions

1 Acquisition

AJU IB Investment acquired 1 company. Their latest acquisition was Gugus on December 10, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/10/2021

$99M

Acq - Fin

1

Date

12/10/2021

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

1

AJU IB Investment Fund History

28 Fund Histories

AJU IB Investment has 28 funds, including 아주 좋은 Life Science 3.0 벤처펀드.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/15/2018

아주 좋은 Life Science 3.0 벤처펀드

$99.12M

3

9/15/2013

AJU New Technolgy Industry Growth Fund

Diversified Private Equity

Open

$160M

1

12/31/2011

KoFC-Aju Pioneer Champ 2011-8 Venture Capital Fund

Multi-Stage Venture Capital

Closed

$38.79M

1

3/17/2011

AJU Agrigento 1

Subscribe to see more

Subscribe to see more

$99M

10

3/4/2011

AJU NAU Growth PEF

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/15/2018

9/15/2013

12/31/2011

3/17/2011

3/4/2011

Fund

아주 좋은 Life Science 3.0 벤처펀드

AJU New Technolgy Industry Growth Fund

KoFC-Aju Pioneer Champ 2011-8 Venture Capital Fund

AJU Agrigento 1

AJU NAU Growth PEF

Fund Type

Diversified Private Equity

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$99.12M

$160M

$38.79M

$99M

$99M

Sources

3

1

1

10

10

AJU IB Investment Team

2 Team Members

AJU IB Investment has 2 team members, including current Chief Executive Officer, President, Jung-Kyoo Yang.

Name

Work History

Title

Status

Jung-Kyoo Yang

Chief Executive Officer, President

Current

Hugo Beekman

President

Current

Name

Jung-Kyoo Yang

Hugo Beekman

Work History

Title

Chief Executive Officer, President

President

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.